1 Engelhard VH, et al. J Immunother Cancer 2020;8:e000262. doi:10.1136/jitc-2019-000262Open access MHC- restricted phosphopeptide antigens: preclinical validation and first- in- humans clinical trial in participants with high- risk melanoma Victor H Engelhard ,1 Rebecca C Obeng ,1 Kara L Cummings,1 Gina R Petroni,2 Angela L Ambakhutwala,1 Kimberly A Chianese- Bullock,3 Kelly T Smith,3 Amanda Lulu,1 Nikole Varhegyi,2 Mark E Smolkin,2 Paisley Myers,4 Keira E Mahoney,4 Jeffrey Shabanowitz,4 Nico Buettner,5 Emily H Hall,6 Kathleen Haden,3 Mark Cobbold,5 Donald F Hunt,4 Geoffrey Weiss,7 Elizabeth Gaughan,7 Craig L Slingluff, Jr3 To cite: Engelhard VH, Obeng RC, Cummings KL, et al. MHC- restricted phosphopeptide antigens: preclinical validation and first- in- humans clinical trial in participants with high- risk melanoma. Journal for ImmunoTherapy of Cancer 2020;8:e000262.